Biotech clinical trials
An approved new drug can cost up to $2.6 billion, making more patient-centric clinical trial design and operation vital for biotech companies.
Operating a decentralised clinical trial (DCT) deployment via a platform such as Atom5TM for a phase II study could save 1-3 months and yield a net benefit that is up to five times greater than the upfront investment, compelling numbers for biotechs looking to decrease their risk when developing new therapies and prove efficacy and safety whilst accelerating their route to market.
Aparito understands the needs of biotechs and has the expertise to develop novel strategies including world-leading digital endpoints and help minimise the financial risk involved in biotech drug development by working as partners with our clients to navigate the regulatory landscape.
Video Assessments, PROs, Telemedicine, EDC and eConsent, all via one smartphone app
Atom5™ provides unparalleled insight into disease burden and disease progression. It captures multiple high-frequency data points from video, voice, wearables, and electronic Patient Reported Outcomes, then analyse the results in conjunction with our team of data scientists to provide rich, real-time insights to clinical teams.
Atom5™ operates under ISO143485 QMS and ISO/IEC 27001 ISMS accreditations and is FDA 21 CFR Part 11 and GDPR compliant.